Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ribociclib dose reduction study in HR+ HER2- advanced breast cancer
NCT03822468Phase 2Completed
- Sponsor
- Novartis
- Start
- Jun 2019
- Primary completion
- Jun 2021
- Modality
- Small Molecules
- Countries
- 23
01
Overview
Phase 2, randomised, open-label trial of ribociclib in breast cancer (2 arms), sponsored by Novartis. Primary endpoint: Overall Response Rate at 23.8 months. Started Jun 2019; status: completed.
02
Drugs
ribociclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03822468.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03822468.